Repligen (RGEN) to Release Quarterly Earnings on Thursday

Repligen (NASDAQ:RGEN) will likely be releasing its Q4 2025 results before the market opens on Thursday, February 19th. Analysts expect the company to announce earnings of $0.44 per share and revenue of $192.2250 million for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 8:30 AM ET.

Repligen Price Performance

Shares of Repligen stock opened at $139.40 on Thursday. Repligen has a twelve month low of $102.96 and a twelve month high of $175.77. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.14 and a current ratio of 8.36. The firm has a market cap of $7.85 billion, a P/E ratio of 6,973.49, a price-to-earnings-growth ratio of 2.61 and a beta of 1.13. The firm’s 50-day simple moving average is $160.47 and its 200-day simple moving average is $145.51.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on RGEN shares. Barclays lifted their price objective on Repligen from $175.00 to $200.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. Wall Street Zen upgraded Repligen from a “hold” rating to a “buy” rating in a report on Saturday, February 7th. Jefferies Financial Group set a $160.00 target price on shares of Repligen and gave the company a “hold” rating in a research note on Tuesday, October 28th. Weiss Ratings downgraded shares of Repligen from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, January 30th. Finally, Canaccord Genuity Group upped their price target on shares of Repligen from $150.00 to $165.00 and gave the company a “hold” rating in a research note on Wednesday, October 29th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $177.92.

Insider Buying and Selling

In other Repligen news, COO James Bylund sold 2,191 shares of the stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $151.21, for a total value of $331,301.11. Following the sale, the chief operating officer directly owned 21,520 shares in the company, valued at $3,254,039.20. This represents a 9.24% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Karen A. Dawes sold 275 shares of the stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $161.00, for a total value of $44,275.00. Following the completion of the sale, the director owned 91,821 shares in the company, valued at $14,783,181. This trade represents a 0.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 4,657 shares of company stock worth $706,877 in the last ninety days. 1.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Repligen

A number of large investors have recently modified their holdings of RGEN. AQR Capital Management LLC bought a new position in shares of Repligen during the 1st quarter valued at $262,000. Jones Financial Companies Lllp increased its holdings in shares of Repligen by 3,850.6% in the first quarter. Jones Financial Companies Lllp now owns 6,400 shares of the biotechnology company’s stock worth $814,000 after buying an additional 6,238 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of Repligen by 16.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 141,994 shares of the biotechnology company’s stock valued at $18,067,000 after acquiring an additional 20,375 shares during the last quarter. Bank of Nova Scotia boosted its holdings in Repligen by 88.0% during the 2nd quarter. Bank of Nova Scotia now owns 31,747 shares of the biotechnology company’s stock valued at $3,951,000 after acquiring an additional 14,860 shares during the period. Finally, Daiwa Securities Group Inc. grew its position in Repligen by 29.7% during the 2nd quarter. Daiwa Securities Group Inc. now owns 31,194 shares of the biotechnology company’s stock worth $3,880,000 after acquiring an additional 7,148 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.